Xylo Bio Achieves Clinical-Stage Milestone with XYL-1001, a Highly Selective Neuroplastogen Targeting Major Depressive Disorder

Phase 1XYL-1001Positive

AI Analysis

Summary

Xylo Bio announced the first participants dosed in a Phase 1 clinical study of XYL-1001, a selective 5-HT2A agonist being developed for Major Depressive Disorder.

Clinical Trial Data

Phase

Phase 1

Outcome Details

First participants dosed in Phase 1 clinical study

Importance:5/10

Sentiment:

0.60

neurotherapypsychiatry5-HT2A agonistclinical milestonephase 1

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 15, 2026 10:00 AM

Read Original